Cedelizumab
Template:Short description Template:Drugbox
Cedelizumab is a monoclonal antibody acting on the immune system.[1] Possible indications include the prevention of organ transplant rejections and the treatment of autoimmune diseases.[2]
It has been approved by both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC).[3]
Vedolizumab is a humanized monoclonal antibody, which binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7) on T lymphocytes to interfere with lymphocyte trafficking to the gut.[3]
References
<templatestyles src="Reflist/styles.css" />
- ↑ WHO Drug Information
- ↑ Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "Citation/CS1".
Script error: No such module "Check for unknown parameters".
Script error: No such module "Navbox". Script error: No such module "Navbox".